clinical trial · NCT07924059
Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia
AchondroplasiaDual therapy with navepegritide and lonapegsomatropinDual therapy with navepegritide and placebo for lonapegsomatropinDual therapy with lonapegsomatropin and placebo for navepegritide
brief summary
This pivotal trial is being conducted to evaluate the efficacy, safety and tolerability of dual therapy with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 17 years.
started
Nov 1, 2026
primary completion
Sep 1, 2028
completion
Sep 1, 2029
last updated
Nov 9, 2026
official title
A Phase 3, Randomized, Double-blind, Active Controlled, Multi-center Trial Investigating the Efficacy and Safety of Dual Therapy With Once-weekly Navepegritide and Once-weekly Lonapegsomatropin Compared to Navepegritide Monotherapy and Lonapegsomatropin Monotherapy in Children and Adolescents With Achondroplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol